FrancophonIA/ELRC3.0 huggingface dataset:
English: In myelofibrosis, patients have too much of these proteins, which cause the production of immature blood cells, some of which migrate to organs such as the spleen, causing them to become enlarged.
Estonian: Müelofibroosiga patsientidel on neid proteiine liiga palju ning seetõttu toodab nende organism ebaküpseid vererakke, millest osa koguneb elunditesse, näiteks põrna, põhjustades elundi suurenemist.
English: Furthermore, the CHMP noted that more information was needed about the starting materials used in the manufacture of Enpaxiq and how it acts on certain target proteins in the body.
Estonian: Peale selle märkis inimravimite komitee, et vaja on lisateavet Enpaxiqi tootmisel kasutatavate lähtematerjalide ning organismi teatavatele sihtproteiinidele avalduva toime kohta.
English: The active substance in Enpaxiq, pacritinib, blocks the action of JAK2 and FLT3, two proteins involved in the production and growth of blood cells.
Estonian: Enpaxiqi toimeaine pakritiniib blokeerib kahe vererakkude moodustumises ja arengus osaleva proteiini, JAK2 ja FLT3 toime.
English: On 20 February 2017, CTI BioPharma officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Enpaxiq, for treating patients with an enlarged spleen or other symptoms of myelofibrosis.
Estonian: CTI BioPharma teatas 20. veebruaril 2017 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Enpaxiq müügiloa taotlus.
English: Given these concerns, the Committee was of the opinion that the benefits of Enpaxiq had not been shown to outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee arvamusel, et Enpaxiqi kasulikkus ei ole suurem kui sellega kaasnevad riskid.
English: Enpaxiq was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 25 August 2010 for different types of myelofibrosis.
Estonian: Enpaxiq nimetati 25. augustil 2010 müelofibroosi harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: At the time of the withdrawal of application, the CHMP was of the provisional opinion that Enpaxiq could not have been approved for myelofibrosis.
Estonian: Taotluse tagasivõtmise ajal oli inimravimite komitee esialgsel arvamusel, et Enpaxiqi kasutamist müelofibroosiga patsientide raviks ei ole võimalik heaks kiita.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Enpaxiq.
Estonian: Ettevõte teatas inimravimite komiteele, et müügiloa andmisest keeldumine ei mõjuta Enpaxiqi kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente.
English: How does Enpaxiq work?
Estonian: Kuidas Enpaxiq toimib?
English: Enpaxiq was expected to be used to treat patients with an enlarged spleen or other symptoms of myelofibrosis - a disorder in which scar tissue builds up in the bone marrow where blood cells are produced.
Estonian: Enpaxiqi kavatseti kasutada suurenenud põrna või muude müelofibroosi (haigus, mille korral tekib sidekoestumine luuüdis, kus moodustuvad vererakud) sümptomitega patsientide raviks.
English: What was Enpaxiq expected to be used for?
Estonian: Milleks kavatseti Enpaxiqi kasutada?
English: What measures are being taken to ensure the safe and effective use of Mulpleo?
Estonian: Mis meetmed võetakse, et tagada Mulpleo ohutu ja efektiivne kasutamine?
English: Mulpleo received a marketing authorisation valid throughout the EU on 18 February 2019.
Estonian: Mulpleo on saanud müügiloa, mis kehtib kogu ELis, 18. veebruaril 2019.
English: Other information about Mulpleo
Estonian: Muu teave Mulpleo kohta
English: Further information on Mulpleo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/mulpleo.
Estonian: Lisateave Mulpleo kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/mulpleo.
English: The European Medicines Agency decided that Mulpleo's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Mulpleo kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: As for all medicines, data on the use of Mulpleo are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Mulpleo kasutamise kohta pidevat järelevalvet.
English: Mulpleo0F (lusutrombopag) EMA/553072/2019
Estonian: Mulpleo0F (lusutrombopaag) EMA/553072/2019
English: What is Mulpleo and what is it used for?
Estonian: Mis on Mulpleo ja milleks seda kasutatakse?
English: Why is Mulpleo authorised in the EU?
Estonian: Miks Mulpleo ELis heaks kiideti?
English: Treatment with Mulpleo should start at least 8 days before the procedure and the recommended dose is 1 tablet daily for 7 days.
Estonian: Ravi Mulpleoga tuleb alustada vähemalt 8 päeva enne protseduuri ja soovitatav annus on 1 tablett ööpäevas 7 päeva jooksul.
English: Side effects reported with Mulpleo are carefully evaluated and any necessary action taken to protect patients.
Estonian: Mulpleo kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: For more information about using Mulpleo, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Mulpleo kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: 1 Previously known as Lusutrombopag Shionogi.
Estonian: 1 Varasem nimetus Lusutrombopag Shionogi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mulpleo have been included in the summary of product characteristics and the package leaflet.
Estonian: Mulpleo ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Mulpleo?
Estonian: Mis riskid Mulpleoga kaasnevad?
English: The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).
Estonian: Ravim on näidustatud patsientidele, kellele tehakse invasiivne protseduur (meditsiiniline protseduur, millega kaasneb nahasisselõige või -punktsioon või instrumendi viimine organismi).
English: Mulpleo contains the active substance lusutrombopag.
Estonian: Mulpleo sisaldab toimeainena lusutrombopaagi.
English: Unwanted effects that occurred in studies are thought to result from patients' medical condition and the nature of the invasive procedure for which Mulpleo was used.
Estonian: Uuringutes tekkinud kõrvalnähud olid arvatavasti tingitud patsientide terviseseisundist ning invasiivsete protseduuride laadist, mille jaoks Mulpleod kasutati.
English: Mulpleo is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to longstanding liver disease.
Estonian: Mulpleo on ravim, mida kasutatakse tugeva verejooksu ennetamiseks kroonilisest maksahaigusest põhjustatud trombotsütopeeniaga täiskasvanutel.
English: Studies have found that Mulpleo increases platelet count, thereby lowering the risk of excessive bleeding during or after an invasive procedure and reducing the need for transfusing platelets.
Estonian: Uuringutes tõendati, et Mulpleo suurendab trombotsüütide arvu, vähendades seeläbi invasiivse protseduuri ajal või järel tugeva verejooksu tekke riski ning trombotsüütide ülekande vajadust.
English: Mulpleo1 (lusutrombopag)
Estonian: (lusutrombopaag)
English: What benefits of Mulpleo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Mulpleo kasulikkus?
English: Mulpleo is available as 3 mg tablets.
Estonian: Mulpleod turustatakse 3 mg tablettidena ja see on retseptiravim.
English: How is Mulpleo used?
Estonian: Kuidas Mulpleod kasutatakse?
English: The active substance in Mulpleo, lusutrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.
Estonian: Mulpleo toimeaine lusutrombopaag seondub samade retseptoritega kui trombopoetiin, aidates suurendada trombotsüütide arvu.
English: The second study involving 215 adults found that 65% of patients who took Mulpleo did not require platelet transfusion before their procedure, compared with 29% of patients who received placebo.
Estonian: Teises uuringus, milles osales 215 täiskasvanut, ei vajanud enne protseduuri trombotsüütide ülekannet 65% Mulpleod kasutanud patsientidest ja 29% platseebot (näiv ravim) kasutanutest.
English: Similar effects occurred in patients receiving placebo.
Estonian: Sarnased nähud esinesid platseebot kasutanud patsientidel.
English: For more information on the side effects and restrictions of Mulpleo, see the package leaflet.
Estonian: Mulpleo kohta teatatud kõrvalnähtude ja piirangute lisateave on pakendi infolehel.
English: The first study, involving 96 adults, found that 79% of patients who took Mulpleo did not require a transfusion of platelets before their procedure, compared with 13% of patients who received placebo (a dummy treatment).
Estonian: Esimeses uuringus, milles osales 96 täiskasvanut, ei vajanud enne protseduuri trombotsüütide ülekannet 79% Mulpleod kasutanud patsientidest ja 13% platseebot (näiv ravim) kasutanutest.
English: In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to receptors (targets) in the bone marrow.
Estonian: Hormoon trombopoetiin stimuleerib organismis trombotsüütide teket, seondudes retseptoritega (sihtmärkidega) luuüdis.
English: Unwanted effects that occurred in studies involving patients taking Mulpleo were headache, nausea (feeling sick), portal vein thrombosis (a blockage in the blood vessel that carries blood from the intestines to the liver) and rash.
Estonian: Uuringutes täheldati Mulpleod kasutanud patsientidel kõrvalnähtudena peavalu, iiveldust, värativeeni tromboosi (trombid veresoones, mis viib verd seedetraktist maksa) ja löövet.
English: How does Mulpleo work?
Estonian: Kuidas Mulpleo toimib?
English: An overview of Mulpleo and why it is authorised in the EU
Estonian: Ülevaade ravimist Mulpleo ja ELis müügiloa väljastamise põhjendus
English: In two main studies involving adults with low levels of platelets due to long-standing liver disease, Mulpleo increased platelet count before an invasive procedure and reduced the need for transfusions.
Estonian: Kahes põhiuuringus, milles osalesid kroonilisest maksahaigusest põhjustatud trombotsütopeeniaga (trombotsüütide vähesus) täiskasvanud, suurendas Mulpleo trombotsüütide arvu enne invasiivset protseduuri ja vähendas transfusioonide (verekomponentide ülekannete) vajadust.
English: You do not need to do anything about it.
Estonian: Te ei pea sellega midagi tegema.
English: Not known (the frequency cannot be determined from the available data):
Estonian: Teadmata (sagedust ei ole võimalik määrata olemasolevate andmete põhjal):
English: This generally takes 30 minutes.
Estonian: Soojenemiseks kulub üldjuhul 30 minutit.
English: Most antibodies were neutralising and persistent.
Estonian: Enamik antikehasid olid neutraliseerivad ja püsivad.
English: This creates a firmer surface.
Estonian: See tekitab tugevama pinna.
English: Date of first authorisation: 8 January 2018
Estonian: Müügiloa esmase väljastamise kuupäev: 8. jaanuar 2018
English: Important!
Estonian: Tähtis!
English: Wash your hands well with soap and water.
Estonian: Peske käed korralikult seebi ja veega.
English: Hold down firmly for 15 seconds.
Estonian: Hoide kindlalt all vähemalt 15 sekundit.
English: Let it air dry.
Estonian: Laske sellel õhu käes kuivada.
English: There may be new information.
Estonian: Siin võib olla uut teavet.
English: • it has been frozen
Estonian: • see on külmunud;
English: Efficacy and safety were consistent with the predecessor trials.
Estonian: Efektiivsus ja ohutus olid kooskõlas eelnenud uuringutega.
English: Long-term safety
Estonian: Pikaajaline ohutus
English: Results shown based on last available data for each variable.
Estonian: Esitatud tulemused põhinevad viimastel olemasolevatel andmetel iga muutuja kohta.
English: However, no data are available in patients over 75 years of age.
Estonian: Kuigi andmed puuduvad üle 75 aastaste patsientide kohta.
English: Individual day and night time scores were similar.
Estonian: Individuaalsed päevaste ja öiste astmasümptomite skoorid olid sarnased.
English: Always use this medicine exactly as your doctor has told you.
Estonian: Kasutage seda ravimit alati täpselt nii, nagu teie arst on teile selgitanud.
English: • it has been dropped or damaged
Estonian: • see on maha kukkunud või kahjustatud;
English: Store in a refrigerator.
Estonian: Säilitada külmkapis.
English: Press down firmly.
Estonian: Vajutage alla tugevalt.
English: Nijmegen, 6545CG Netherlands
Estonian: Nijmegen, 6545CG Holland
English: Such reactions may happen within hours or days after the injection.
Estonian: Sellised reaktsioonid võivad tekkida tundide või päevade jooksul pärast süsti saamist.
English: It is not known whether Fasenra could harm your unborn baby.
Estonian: Ei ole teada, kas Fasenra võib teie sündimata last kahjustada.
English: Common (these may affect up to 1 in 10 people):
Estonian: Sage (võib esineda kuni 1 inimesel 10-st):
English: Median percent reduction
Estonian: Protsentuaalse vähenemise mediaan
English: • through clothing
Estonian: • läbi riiete.
English: Table 5 summarizes the study results for Trial 3.
Estonian: Tabelis 5 on esitatud uuringu 3 tulemuste kokkuvõte.
English: Children and adolescents The safety and benefits of this medicine are not known in children below the age of 18.
Estonian: Lapsed ja noorukid Selle ravimi ohutus ja tõhusus alla 18-aastastel lastel ei ole teada.
English: Store in a refrigerator (2°C to 8°C).
Estonian: Säilitada külmkapis (2 °C…8 °C).
English: Open here
Estonian: Ava siit.
English: Go straight on to the next steps, without delay.
Estonian: Jätkake ilma viivitusteta järgmiste sammudega.
English: Number of patients (n) varies slightly due to the number of patients for whom data were available for each variable.
Estonian: Patsientide arv (n) varieerub kergelt nende patsientide tõttu, kellelt saadi andmeid iga muutuja kohta.
English: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Estonian: Sobivusuuringute puudumise tõttu ei tohi seda ravimit teiste ravimitega segada.
English: These reactions may occur within hours of administration, but in some instances have a delayed onset (i.e. days).
Estonian: Need reaktsioonid võivad ilmneda manustamisele järgnenud tundide jooksul, kuid mõnedel juhtudel hiljem (s.o järgnevate päevade jooksul).
English: d. EOT for Trial 4 was Week 48 (the last timepoint for adults and adolescent data).
Estonian: d. Uuringu 4 EOT oli 48. nädal (täiskasvanute ja noorukite andmete viimane ajapunkt).
English: Currently available data in children 12 to less than 18 years old are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.
Estonian: Hetkel olemasolevad andmed 12 kuni alla 18-aastaste laste kohta on välja toodud lõikudes 4.8, 5.1 ja 5.2, kuid soovitusi annustamise kohta ei saa nende põhjal anda.
English: It may contain particles.
Estonian: See võib sisaldada osakesi.
English: No dedicated animal studies have been conducted.
Estonian: Ühtki asjakohast loomkatset ei ole läbi viidud.
English: Risk to the breast-fed child cannot be excluded.
Estonian: Ohtu imikutele ei saa välistada.
English: It may contain small white particles.
Estonian: Lahus võib sisaldada väikseid valgeid osakesi.
English: MedImmune UK Ltd 6 Renaissance Way Liverpool, L24 9JW United Kingdom
Estonian: MedImmune UK Ltd 6 Renaissance Way Liverpool, L24 9JW Ühendkuningriik
English: Total duration of treatment: 104 - 112 weeks
Estonian: Ravi kogukestus: 104...112 nädalat
English: The overall adverse event profile was similar to the asthma trials described above.
Estonian: Kõrvaltoimete üldine profiil oli sarnane eespool kirjeldatud astma uuringutes täheldatuga.
English: You will hear a second ‘click'.
Estonian: Te kuulete teist „klõpsatust“.
English: The most commonly reported adverse reactions during treatment are headache (8%) and pharyngitis (3%).
Estonian: Enim teatatud kõrvaltoimed ravi kestel on peavalu (8%) ja farüngiit (3%).
English: b. Integrated analysis of Trial 1 and 2 baseline includes adults and adolescents.
Estonian: b. Uuringute 1 ja 2 algväärtuste integreeritud analüüs hõlmab täiskasvanuid ja noorukeid.
English: No data are available for children aged 6 to 11 years old.
Estonian: 6 kuni 11 aastaste laste osas andmed puuduvad.
English: Benra 30 mg q. 8 weeks n =
Estonian: Benra 30 mg q. 8 nädalat
English: Its administration to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
Estonian: Selle kasutamist raseduse ajal võib kaaluda vaid siis, kui oodatav kasu emale on suurem kui võimalik oht lootele.
English: This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Estonian: See teave ei asenda vestlust tervishoiutöötajaga teie terviseseisundist või ravist.
English: The green needle guard is now exposed.
Estonian: Roheline nõelakaitse on nüüd nähtaval.
English: For example, do not warm it in a microwave or hot water, or put it near other heat sources.
Estonian: Näiteks ärge soojendage seda mikrolaineahjus ega veevannis ega asetage muude soojusallikate lähedusse.
English: n= number of patients with data at timepoint.
Estonian: n = sel ajahetkel saadaval olevate andmetega patsientide arv.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Estonian: Täpne teave selle ravimpreparaadi kohta on Euroopa Ravimiameti kodulehel http://www.ema.europa.eu.
English: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Estonian: Igas esinemissageduse rühmas on kõrvaltoimed esitatud nende tõsiduse vähenemise järjekorras.
English: For each injection, choose a different site that is at least 3 cm away from where you last injected.
Estonian: Valige iga süste jaoks erinev koht, mis on vähemalt 3 cm kaugusel eelmisest.
English: Week(s)
Estonian: Nädal(ad)
English: Rate a.
Estonian: Määr a.
English: Following subcutaneous administration, the elimination half-life was approximately 15.5 days.
Estonian: Subkutaanse manustamise järel oli eritumise poolväärtusaeg ligikaudu 15,5 päeva.
English: Open the carton.
Estonian: Avage pakend.
English: Allergic reactions have occurred in patients receiving this medicine.
Estonian: Seda ravimit kasutanud patsientidel on esinenud allergilisi reaktsioone.
English: It is there to prevent you from touching the needle.
Estonian: See takistab teil puudutamast nõela.
English: The first 3 injections are every 4 weeks.
Estonian: Esimesed 3 annust süstitakse iga 4 nädala tagant.
English: You could cause the injection to happen too soon or damage the needle.
Estonian: Te võite sellega põhjustada liiga varajast süstimist või kahjustada nõela.
English: If the green plunger does not fill the viewing window, you may not have received the full dose.
Estonian: Kui roheline kolb ei täida vaatlusava, siis tähendab see seda, et te ei saanud kogu annust.
English: Common Not known
Estonian: Sage Teadmata
English: If this happens or if you have any other concerns, call your healthcare provider.
Estonian: Kui selline asi juhtub või kui teil on mingeid muid probleeme, pöörduge oma tervishoiuteenuse osutaja poole.
English: Difference
Estonian: Erinevus
English: • the expiry date (EXP) has passed
Estonian: • kõlblikkusaeg (EXP) on möödas.
English: Other medicines and Fasenra
Estonian: Muud ravimid ja Fasenra
English: Gender, Race
Estonian: Sugu, rass
English: You will hear a click.
Estonian: Te kuulete klõpsatust.
English: You and your doctor or nurse should decide if you should inject Fasenra yourself.
Estonian: Teie ja teie arst või meditsiiniõde peate/peavad otsustama, kas te tohite ise Fasenrat süstida.
English: Serious allergic reactions
Estonian: Rasked allergilised reaktsioonid
English: The long-term efficacy and safety of Fasenra was evaluated in a phase 3, 56-week extension trial BORA (Trial 4).
Estonian: Fasenra pikaajalist efektiivsust ja ohutust hinnati III faasi 56-nädalases jätku-uuringus BORA (uuring 4).
English: • into the 5 cm area around your belly-button
Estonian: • 5 cm piirkonda naba ümbruses;
English: The liquid should be clear and colourless to yellow.
Estonian: Lahus peab olema selge ja värvusetu kuni kollane.
English: Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases, ATC code: R03DX10
Estonian: Farmakoterapeutiline rühm: hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, teised süsteemse toimega hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, ATC-kood: R03DX10
English: Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.
Estonian: Patsientidele tuleb öelda, et nad pöörduksid arsti poole, kui nende astma ei allu endiselt ravile või süveneb pärast ravi alustamist.
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Estonian: Tervishoiutöötajatel palutakse teavitada kõigist võimalikest kõrvaltoimetest riikliku teavitamissüsteemi, mis on loetletud lisas V, kaudu.
English: The second click tells you the injection has finished.
Estonian: Teine klõpsatus tähendab, et süstimine on lõppenud.
English: It is preferable to avoid the use of Fasenra during pregnancy.
Estonian: Raseduse ajal on soovitatav Fasenra kasutamisest hoiduda.
English: You should not inject Fasenra yourself if you have not received Fasenra previously and if you had previous allergic reaction with Fasenra.
Estonian: Te ei tohi Fasenrat ise süstida, kui te ei ole varem Fasenra ravi saanud ja kui teil on varem esinenud Fasenraga allergilisi reaktsioone.
English: Median percent reductions in daily OCS over time (Trial 3 and 4)
Estonian: Päevase SKS-i protsentuaalse vähenemise mediaan aja jooksul (uuringud 3 ja 4)
English: For the full list of excipients, see section 6.1.
Estonian: Abiainete täielik loetelu kohta vt lõik 6.1.
English: If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.
Estonian: Üleannustamise korral tuleb patsienti ravida toetavalt, vajaduse korral koos asjakohase jälgimisega.
English: Patients were permitted to enter a second extension trial after a minimum of 8 weeks in Trial 4 without completing the 56-week extension period.
Estonian: Patsientidel lubati alustada osalemist teises jätkuuuringus pärast minimaalselt kaheksat nädalat uuringus 4 ja enne 56-nädalase pikendusperioodi lõpetamist.
English: Asthma symptom scale: total score from 0 (least) to 6 (most); day and night time asthma symptom scores from 0 (least) to 3 (most) symptoms.
Estonian: Astmasümptomite skaala: üldskoor 0 (vähim) kuni 6 (enim); päevaste ja öiste astmasümptomite skoorid 0 (vähim) kuni 3 (enim) sümptomit.
English: Fasenra is intended for long-term treatment.
Estonian: Fasenra on mõeldud pikaajaliseks raviks.
English: Do not use this medicine after the expiry date which is stated on the label.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud sildil.
English: The trial included an 8-week run-in period during which the OCS was titrated to the minimum effective dose without losing asthma control.
Estonian: Uuring sisaldas 8 nädala pikkust sissejuhatavat perioodi, mille jooksul SKS reguleeriti minimaalse efektiivse annuseni, ilma et astma kontrolli alt väljuks.
English: • fever (high temperature)
Estonian: • palavik (kõrge kehatemperatuur);
English: If the healthcare professional or caregiver administers the injection, the upper arm can also be used.
Estonian: Kui süsteravimit manustab tervishoiutöötaja või hooldaja, võib kasutada ka käsivarre ülaosa.